Edgewise Therapeutics, Inc.
EWTX
Rank in Stocks
#4059
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Share Price
$37.15
Last synced: 2026-10-16
Market Cap
$4.00B
Change (1 day)
-2.75%
Change (1 year)
146.68%
Country
US
Trade Edgewise Therapeutics, Inc. (EWTX)
Category
Healthcare
EPS for Edgewise Therapeutics, Inc. (EWTX)
EPS as of June 2026 TTM: $-1.85
According to Edgewise Therapeutics, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-1.85. At the end of 2023 the company had a EPS of $-1.57 an increase over its 2022 EPS that were of $-1.26.
EPS history for Edgewise Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
